Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.3% – Should You Sell?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was down 7.3% during mid-day trading on Friday . The stock traded as low as $3.88 and last traded at $3.9850. Approximately 7,668,251 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 15,027,618 shares. The stock had previously closed at $4.30.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks Research raised its FY2026 earnings estimate for Iovance Biotherapeutics and also nudged up expectations for Q2 2026, Q1 2027, Q2 2027, and Q1 2028, suggesting improving near-term outlook and some progress toward narrowing losses.
• Positive Sentiment: A Zacks article argued that Iovance’s commercial momentum and expanding Amtagvi pipeline make it look better positioned than Agenus, which may support investor sentiment around the company’s growth story. Article Title
• Neutral Sentiment: Analysts still expect Iovance to post losses across the forecast period, including a consensus full-year loss estimate of about $0.63 per share, so the company remains a turnaround story rather than a profitable one.
• Negative Sentiment: Zacks Research lowered several longer-term estimates, including Q3 2026, Q4 2026, Q3 2027, Q4 2027, and FY2028, which may temper enthusiasm by implying a slower earnings recovery farther out.

Analysts Set New Price Targets

Several analysts recently issued reports on IOVA shares. Wall Street Zen raised shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays upped their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Chardan Capital reduced their target price on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 target price on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Iovance Biotherapeutics has an average rating of “Hold” and a consensus target price of $8.43.

Iovance Biotherapeutics Stock Performance

The stock has a market cap of $1.83 billion, a P/E ratio of -4.32 and a beta of 0.69. The company’s 50 day moving average price is $3.66 and its 200-day moving average price is $3.12.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The firm had revenue of $71.43 million during the quarter, compared to analyst estimates of $77.84 million. During the same quarter in the prior year, the business posted ($0.36) EPS. The business’s revenue was up 44.9% compared to the same quarter last year. On average, analysts forecast that Iovance Biotherapeutics, Inc. will post -0.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares during the last quarter. State Street Corp boosted its holdings in shares of Iovance Biotherapeutics by 51.5% in the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after buying an additional 6,851,486 shares during the last quarter. Invenomic Capital Management LP boosted its holdings in shares of Iovance Biotherapeutics by 13.5% in the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock worth $32,649,000 after buying an additional 1,417,897 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 30.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after buying an additional 2,032,062 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Iovance Biotherapeutics by 16.4% in the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock worth $21,821,000 after buying an additional 1,123,337 shares during the last quarter. 77.03% of the stock is owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.